AI Article Synopsis

  • The study compares the effectiveness of the levonorgestrel 52-mg intrauterine device (IUD) and the copper T380A IUD for emergency contraception in terms of 1-year pregnancy and continuation rates.
  • Conducted as a randomized noninferiority trial in Utah family planning clinics, the study monitored participants over a year to track pregnancy outcomes and reasons for discontinuation.
  • Results showed that pregnancy rates were similar for both IUD types, with 2.8% for levonorgestrel and 3.0% for copper, indicating no significant difference in their effectiveness as emergency contraception.

Article Abstract

Background: Recent evidence demonstrates the effectiveness of the levonorgestrel 52-mg intrauterine device for emergency contraception vs the copper T380A intrauterine device. Of note, 1-year pregnancy and continuation rates after intrauterine device placement for emergency contraception remain understudied.

Objective: This study compared 1-year pregnancy and intrauterine device continuation rates and reasons for discontinuation among emergency contraception users randomized to the levonorgestrel 52-mg intrauterine device or the copper intrauterine device.

Study Design: This participant-masked, randomized noninferiority trial recruited emergency contraception individuals desiring an intrauterine device from 6 Utah family planning clinics between August 2016 and December 2019. Participants were randomized 1:1 to the levonorgestrel 52-mg intrauterine device group or the copper T380A intrauterine device group. Treatment allocation was revealed to participants at the 1-month follow-up. Trained personnel followed up the participants by phone, text, or e-mail at 5 time points in 1 year and reviewed electronic health records for pregnancy and intrauterine device continuation outcomes for both confirmation and nonresponders. We assessed the reasons for the discontinuation and used Cox proportional-hazard models, Kaplan-Meier estimates, and log-rank tests to assess differences in the continuation and pregnancy rates between the groups.

Results: The levonorgestrel and copper intrauterine device groups included 327 and 328 participants, respectively, receiving the respective interventions. By intention-to-treat analysis at 1 year, the pregnancy rates were similar between intrauterine device types (2.8% [9/327] in levonorgestrel 52-mg intrauterine device vs 3.0% [10/328] in copper intrauterine device; risk ratio, 0.9; 95% confidence interval, 0.4-2.2; P=.82). Most pregnancies occurred in participants after intrauterine device removal, with only 1 device failure in each group. Of note, 1-year continuation rates did not differ between groups with 204 of 327 levonorgestrel 52-mg intrauterine device users (62.4%) and 183 of 328 copper T380A intrauterine device users (55.8%) continuing intrauterine device use at 1 year (risk ratio, 1.1; 95% confidence interval, 1.0-1.2; P=.09). There were differences concerning the reasons for discontinuation between intrauterine device types, with more bleeding and cramping cited among copper intrauterine device users.

Conclusion: The pregnancy rates were low and similar between intrauterine device types. Of note, 6 of 10 intrauterine device emergency contraception users continued use at 1 year. Moreover, 1-year continuation rates were similar between intrauterine device types.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10065890PMC
http://dx.doi.org/10.1016/j.ajog.2022.11.1296DOI Listing

Publication Analysis

Top Keywords

intrauterine device
88
intrauterine
24
emergency contraception
24
device
23
continuation rates
20
copper intrauterine
20
levonorgestrel 52-mg
20
52-mg intrauterine
20
device types
16
copper t380a
12

Similar Publications

Introduction: The intrauterine device (IUD) inserted immediately after delivery is a safe and effective measure for preventing unplanned pregnancies. Despite exhibiting a higher expulsion rate compared with later insertions, it proves cost-effective due to the high rate of continuity of the method. There is still a gap in the literature regarding the optimal strategy for monitoring these patients, whether it should be through clinical examination, ultrasound or both.

View Article and Find Full Text PDF

Fertility Sparing in Endometrial Cancer: Where Are We Now?

Cancers (Basel)

January 2025

Department of Molecular and Developmental Medicine, Obstetrics and Gynecological Clinic, University of Siena, 53100 Siena, Italy.

Endometrial cancer is the most common gynecological neoplasm with an increased incidence in the premenopausal population in recent decades. This raises the problem of managing endometrial cancer in fertile women who have not yet achieved pregnancy. In these women, after careful selection, hysterectomy may be postponed in favor of conservative management if specific requirements are met.

View Article and Find Full Text PDF

Anti-Adhesive Podocalyxin Expression Is Disrupted in Recurrent Implantation Failure.

Diagnostics (Basel)

January 2025

Department of Obstetrics and Gynecology, IVF-Unit, Acibadem Kayseri Hospital, 38140 Kayseri, Türkiye.

The downregulation of anti-adhesive regulatory proteins and upregulation of adhesive genes are critical for the receptive endometrium. This study was designed to determine whether switching between the anti-adhesive podocalyxin (PDX) and adhesive HOXA10 receptivity modulator occurs in the endometrium of women with recurrent implantation failure (RIF). Twenty-four patients with RIF who could not conceive for three or more cycles despite good-quality embryo transfer constituted the study group.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!